Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
- Published Date : May 21, 2025
- Updated On : December 16, 2025
- Pages : 58
Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Emerging Therapy and TPP Insights
Thelansis’s “Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Overview
Relapsed or refractory myelodysplastic syndromes represent a group of clonal bone marrow disorders characterized by ineffective hematopoiesis, cytopenias, and risk of progression to acute myeloid leukemia. Patients with R/R MDS have either failed to respond to initial therapies, most commonly hypomethylating agents such as azacitidine or decitabine, or have relapsed after an initial response. Clinically, these patients experience persistent anemia, infections due to neutropenia, and bleeding complications from thrombocytopenia, all of which contribute to poor quality of life and high healthcare utilization. Treatment options are limited, with allogeneic stem cell transplantation being the only potentially curative approach, though many patients are ineligible due to age or comorbidities. Novel agents targeting epigenetic pathways, apoptosis regulators, and immune checkpoints are under investigation, but outcomes remain poor and survival is short once standard therapies fail. The lack of effective salvage options highlights a significant unmet need for innovative therapies that can improve survival and alter disease progression, making R/R MDS a critical focus area in hematology drug development.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Emerging Therapy and TPP Insights
Thelansis’s “Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Overview
Relapsed or refractory myelodysplastic syndromes represent a group of clonal bone marrow disorders characterized by ineffective hematopoiesis, cytopenias, and risk of progression to acute myeloid leukemia. Patients with R/R MDS have either failed to respond to initial therapies, most commonly hypomethylating agents such as azacitidine or decitabine, or have relapsed after an initial response. Clinically, these patients experience persistent anemia, infections due to neutropenia, and bleeding complications from thrombocytopenia, all of which contribute to poor quality of life and high healthcare utilization. Treatment options are limited, with allogeneic stem cell transplantation being the only potentially curative approach, though many patients are ineligible due to age or comorbidities. Novel agents targeting epigenetic pathways, apoptosis regulators, and immune checkpoints are under investigation, but outcomes remain poor and survival is short once standard therapies fail. The lack of effective salvage options highlights a significant unmet need for innovative therapies that can improve survival and alter disease progression, making R/R MDS a critical focus area in hematology drug development.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)